Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Psychemedics Corp (PMD) Common Stock USD0.005

Sell:$6.50 Buy:$9.00 Change: $0.08 (0.95%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.08 (0.95%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.08 (0.95%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. The Company’s testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customize its enzyme immunoassay (EIA) procedures to drug test hair samples. The Company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines, opiates, synthetic cannabinoids, benzodiazepines, nicotine and fentanyl. The Company’s testing process is used by police departments, Federal Reserve Banks, schools, and other public entities

Contact details

125 Nagog Park Ste 200
United States
+1 (800) 6288073

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$46.55 million
Shares in issue:
5.54 million
Health Care Services
United States
US dollar

Key personnel

  • Raymond Kubacki
    Chairman of the Board, President, Chief Executive Officer
  • Charles Doucot
    Executive Vice President
  • Michael Schaffer
    Vice President - Laboratory Operations
  • Andrew Limbek
    Vice President, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.